Kevin Bhatt

Kevin Bhatt has contributed to clinical investigation of alpha-specific PI3K inhibitors including alpelisib in patients with PIK3CA-mutated HR+/HER2- advanced breast cancer. His research has examined predictive biomarkers beyond PIK3CA hotspot mutations that identify patients most likely to benefit from alpelisib plus fulvestrant, and has investigated mechanisms of resistance to alpelisib in PIK3CA-mutated disease. He has studied the management of hyperglycemia and other class-specific toxicities of PI3K alpha inhibition that represent major challenges to patient tolerability and treatment adherence. His translational work bridges PI3K pathway biology, genomic testing strategies for PIK3CA mutation detection, and clinical outcomes in patients with PI3K-pathway-activated HR+ metastatic breast cancer.